These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26864725)

  • 21. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
    Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
    J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
    Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
    Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of NOTCH1 signaling in T-ALL.
    Ferrando AA
    Hematology Am Soc Hematol Educ Program; 2009; ():353-61. PubMed ID: 20008221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression.
    Cialfi S; Palermo R; Manca S; Checquolo S; Bellavia D; Pelullo M; Quaranta R; Dominici C; Gulino A; Screpanti I; Talora C
    Leukemia; 2013 Feb; 27(2):485-8. PubMed ID: 22846929
    [No Abstract]   [Full Text] [Related]  

  • 25. Synergistic antileukemic therapies in
    Sanchez-Martin M; Ambesi-Impiombato A; Qin Y; Herranz D; Bansal M; Girardi T; Paietta E; Tallman MS; Rowe JM; De Keersmaecker K; Califano A; Ferrando AA
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2006-2011. PubMed ID: 28174276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
    Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
    Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.
    Pajcini KV; Xu L; Shao L; Petrovic J; Palasiewicz K; Ohtani Y; Bailis W; Lee C; Wertheim GB; Mani R; Muthusamy N; Li Y; Meijerink JPP; Blacklow SC; Faryabi RB; Cherry S; Pear WS
    Sci Signal; 2017 Nov; 10(505):. PubMed ID: 29138297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia.
    Guo D; Teng Q; Ji C
    Leuk Lymphoma; 2011 Jul; 52(7):1200-10. PubMed ID: 21463127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The genetics and mechanisms of T cell acute lymphoblastic leukaemia.
    Belver L; Ferrando A
    Nat Rev Cancer; 2016 Jul; 16(8):494-507. PubMed ID: 27451956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia.
    Herranz D; Ambesi-Impiombato A; Sudderth J; Sánchez-Martín M; Belver L; Tosello V; Xu L; Wendorff AA; Castillo M; Haydu JE; Márquez J; Matés JM; Kung AL; Rayport S; Cordon-Cardo C; DeBerardinis RJ; Ferrando AA
    Nat Med; 2015 Oct; 21(10):1182-9. PubMed ID: 26390244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stabilization of Notch1 by the Hsp90 Chaperone Is Crucial for T-Cell Leukemogenesis.
    Wang Z; Hu Y; Xiao D; Wang J; Liu C; Xu Y; Shi X; Jiang P; Huang L; Li P; Liu H; Qing G
    Clin Cancer Res; 2017 Jul; 23(14):3834-3846. PubMed ID: 28143869
    [No Abstract]   [Full Text] [Related]  

  • 32. Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial.
    Jenkinson S; Kirkwood AA; Goulden N; Vora A; Linch DC; Gale RE
    Leukemia; 2016 Jan; 30(1):39-47. PubMed ID: 26220040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia.
    Albertí-Servera L; Demeyer S; Govaerts I; Swings T; De Bie J; Gielen O; Brociner M; Michaux L; Maertens J; Uyttebroeck A; De Keersmaecker K; Boeckx N; Segers H; Cools J
    Blood; 2021 Feb; 137(6):801-811. PubMed ID: 32812017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells.
    Lian H; Li D; Zhou Y; Landesman-Bollag E; Zhang G; Anderson NM; Tang KC; Roderick JE; Kelliher MA; Seldin DC; Fu H; Feng H
    Haematologica; 2017 Jan; 102(1):e17-e21. PubMed ID: 27758824
    [No Abstract]   [Full Text] [Related]  

  • 35. Friend or foe: can activating mutations in NOTCH1 contribute to a favorable treatment outcome in patients with T-ALL?
    Goldshtein A; Berger M
    Crit Rev Oncog; 2014; 19(5):399-404. PubMed ID: 25404153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Tumor Suppressor Enhancer of
    Tottone L; Lancho O; Loh JW; Singh A; Kimura S; Roels J; Kuchmiy A; Strubbe S; Lawlor MA; da Silva-Diz V; Luo S; Gachet S; García-Prieto CA; Hagelaar R; Esteller M; Meijerink JPP; Soulier J; Taghon T; Van Vlierberghe P; Mullighan CG; Khiabanian H; Rocha PP; Herranz D
    Blood Cancer Discov; 2021 Jan; 2(1):92-109. PubMed ID: 33458694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
    Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
    Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.
    Gusscott S; Jenkins CE; Lam SH; Giambra V; Pollak M; Weng AP
    PLoS One; 2016; 11(8):e0161158. PubMed ID: 27532210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Notch in T-ALL: new players in a complex disease.
    Koch U; Radtke F
    Trends Immunol; 2011 Sep; 32(9):434-42. PubMed ID: 21775206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia.
    Waibel M; Vervoort SJ; Kong IY; Heinzel S; Ramsbottom KM; Martin BP; Hawkins ED; Johnstone RW
    Leukemia; 2018 Jan; 32(1):237-241. PubMed ID: 28914259
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.